![]() ![]() Dubbed DEN-NOAC, the trial will be led by Casper Bang, MD (Rigshospitalet, Copenhagen, Denmark). At the end of the 4-year period, every participating hospital will have 1 year’s experience with each of the approved NOACs, with follow-up to continue for several years thereafter. Designed to run for 4 years, each hospital will just use one of the four approved NOACs (,, , and ) for the period of 1 year, then the next the next year, and so forth. told TCTMD that a new prospective, cluster randomized trial has just been announced in Denmark that will involve “almost all” hospitals in the country. To date there are no randomized head-to-head trials comparing the new agents, but that is about to change. In that analysis, and were associated with a significantly decreased risk of ICH compared with warfarin, but was not, although all three were as effective as warfarin at reducing stroke in atrial fibrillation patients…. The two new studies come close on the heels of an analysis by Danish researchers comparing, ,, and warfarin. We get these insights from this Octoarticle, “More NOAC Comparisons See Higher Bleeding Risk With Rivaroxaban: Is the ‘Writing on the Wall’?”: ![]() In two medical study reports it seemed that Xarelto (rivaroxaban) was more likely to be involved in a serious bleeding event as an adverse reaction than was either Pradaxa (dabigatran) or Eliquis (apixaban).Įarlier this month the medical journal Chest published this article, “Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation”.Īlso earlier this month, JAMA Internal Medicine published this article, “Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation.” ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |